L-DOPA/DDCI — Competitive Intelligence Brief

L-DOPA/DDCI (L-DOPA/DDCI) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Dopamine precursor with peripheral decarboxylase inhibitor. Area: Neurology.

marketed Dopamine precursor with peripheral decarboxylase inhibitor Aromatic amino acid decarboxylase (AADC); dopaminergic system Neurology Small molecule

Target snapshot

L-DOPA/DDCI (L-DOPA/DDCI) — Bial - Portela C S.A.. L-DOPA is converted to dopamine in the brain to replace deficient neurotransmitter levels, while DDCI (a decarboxylase inhibitor) prevents premature conversion of L-DOPA in the periphery, allowing more to reach the central nervous system.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
L-DOPA/DDCI TARGET	L-DOPA/DDCI	Bial - Portela C S.A.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopaminergic system
Levodopa / Carbidopa	Levodopa / Carbidopa	Ross D. Zafonte, MD	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (AADC); dopamine pathway
Levodopa and carbidopa	Levodopa and carbidopa	NeuroDerm Ltd.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (inhibited by carbidopa)
Levodopa Benserazide Madopar	Levodopa Benserazide Madopar	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic amino acid decarboxylase (inhibited by benserazide)
Levodopa + benserazide	Levodopa + benserazide	University of Buenos Aires	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Dopamine pathway; aromatic L-amino acid decarboxylase (peripheral inhibition)
Levodopa Benserazide Teva Italia	Levodopa Benserazide Teva Italia	IRCCS San Raffaele Roma	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic amino acid decarboxylase (inhibited by benserazide); dopamine receptors (target of levodopa-derived dopamine)
Sinemet (comparator)	Sinemet (comparator)	XenoPort, Inc.	marketed	Dopamine precursor with peripheral decarboxylase inhibitor	Aromatic L-amino acid decarboxylase (AADC); dopaminergic system

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Dopamine precursor with peripheral decarboxylase inhibitor class)

1. Bial - Portela C S.A. · 2 drugs in this class
2. IRCCS San Raffaele Roma · 2 drugs in this class
3. NeuroDerm Ltd. · 1 drug in this class
4. Pfizer · 1 drug in this class
5. Ross D. Zafonte, MD · 1 drug in this class
6. University of Buenos Aires · 1 drug in this class
7. AbbVie · 1 drug in this class
8. XenoPort, Inc. · 1 drug in this class
9. Intec Pharma Ltd. · 1 drug in this class